Abeona

ABEO NASDAQ
7.01
-0.41
-5.53%
After Hours: 7.01 0 0.00% 16:51 05/22 EDT
Open
7.35
Prev Close
7.42
High
7.45
Low
6.99
Volume
424.66K
Avg Vol (3M)
399.45K
52 Week High
18.90
52 Week Low
6.26
% Turnover
0.86%
Market Cap
344.63M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Abeona ABEO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
MORE >

Recently

Name
Price
%Change